Clinical trial NCT02407340: Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder
Official title: Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alcoholism
Alcohol Related Disorders
Keywords: Alcohol Withdrawal Delirium
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2015-04-02
Enrollment: 27
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Oxytocin vs. placebo
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the utility of the neuropeptide oxytocin (OT) as a potential new medication for the treatment of Alcohol use disorder (AUD). Non-treatment seeking men and women with AUD will be enrolled in a double blind placebo controlled phase I clinical trial. Participants will complete an 7-day inpatient protocol. During the first 3 days of the inpatient protocol, participants will complete alcohol abstinence in which withdrawal symptoms are measured,and urine will be collected to determine withdrawal symptom severity and urine levels of the stress hormone cortisol. Participants will then complete 3 laboratory procedures which measure 1) stress response, 2) motivation to drink alcohol and 3) subjective and physiological effects of alcohol. Finally, because participants are individuals with AUD, investigators will administer a brief intervention to address their risky alcohol drinking and problems before discharge.

Detailed description: This study will lay the necessary groundwork for future comprehensive research to examine the utility of the neuropeptide oxytocin (OT) as a potential new medication for the treatment of Alcohol use disorder (AUD). OT modulates a number of key systems involved in addiction processes, including dopamine (DA) mesolimbic reward circuitry, and hypothalamic-pituitary-adrenal (HPA) axis and corticotrophin-releasing factor (CRF) stress systems, and has low abuse liability. Our overarching hypothesis is that OT will attenuate several measures thought to drive compulsive alcohol drinking and relapse. Specifically, investigators will examine whether OT decreases acute stress responses, alleviates alcohol withdrawal symptoms, reduces craving and motivation to drink, and decreases alcohol self-administration. Since interactions with alcohol are an important focus of our study, investigators will enroll non-treatment seeking heavy drinkers with AUD in a double blind, placebo controlled inpatient protocol. Subjects will be randomized to receive intranasal OT (40 IU/dose) or placebo 3 times daily. Participants will complete alcohol detoxification; investigators will measure alcohol withdrawal symptoms, craving, and 24-hr urinary free CORT. Participants will then complete 3 laboratory procedures in fixed order. The Trier Social Stress Test (TSST) which includes public speaking and performance of mental arithmetic will be used to examine subjective and physiological stress responses. An alcohol motivated responding (AMR) procedure will be used to examine subjects' responding to earn either drinks or money. A cumulative alcohol-dosing (CAD) procedure will be used to examine physiological and subjective responses across several blood alcohol levels. cortisol (CORT) levels will also be assessed. This study will provide new information on OT efficacy across a range of different measures predictive of alcohol use and misuse, and, if OT shows efficacy, help clarify the mechanism of OT action.

Eligibility criteria: Inclusion Criteria:

* Healthy 21-50 years old male and female subjects
* Must meet Diagnostic and Statistical Manual (DSM) -V criteria for AUD and not be seeking treatment
* Actively drinking
* Positive blood phosphatidylethanol (PEth) blood test

Exclusion Criteria:

* Current DSM-V major current mood or anxiety disorder or drug use disorder (excluding alcohol and nicotine use disorders, and moderate-severe cannabis use disorder); in or in need of treatment
* Drug use in last 30 days and/or positive urine toxicology screens (excluding marijuana)
* History of seizure disorder or closed head trauma
* History of withdrawal-related seizures or serious alcohol withdrawal symptoms
* HIV positive
* Neuroendocrine disorder
* Any serious medical condition that would place subject at risk or interfere with study participation
* Liver function tests more than 3 times normal at screening
* Prescription medications in last 3 months that could affect central nervous system or HPA axis function
* Women who are pregnant, nursing or planning pregnancy cannot participate

Primary outcomes:
measure: Alcohol drinking
timeFrame: 1 day
Secondary outcomes:
measure: alcohol effects
timeFrame: 1 day
measure: side effects
timeFrame: 1 week
measure: Salivary cortisol
timeFrame: 1 day
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Elise Weerts, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: